These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 28611092)

  • 1. Altering Metabolic Profiles of Drugs by Precision Deuteration 2: Discovery of a Deuterated Analog of Ivacaftor with Differentiated Pharmacokinetics for Clinical Development.
    Harbeson SL; Morgan AJ; Liu JF; Aslanian AM; Nguyen S; Bridson GW; Brummel CL; Wu L; Tung RD; Pilja L; Braman V; Uttamsingh V
    J Pharmacol Exp Ther; 2017 Aug; 362(2):359-367. PubMed ID: 28611092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial.
    Ratjen F; Hug C; Marigowda G; Tian S; Huang X; Stanojevic S; Milla CE; Robinson PD; Waltz D; Davies JC;
    Lancet Respir Med; 2017 Jul; 5(7):557-567. PubMed ID: 28606620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.
    Wainwright CE; Elborn JS; Ramsey BW; Marigowda G; Huang X; Cipolli M; Colombo C; Davies JC; De Boeck K; Flume PA; Konstan MW; McColley SA; McCoy K; McKone EF; Munck A; Ratjen F; Rowe SM; Waltz D; Boyle MP; ;
    N Engl J Med; 2015 Jul; 373(3):220-31. PubMed ID: 25981758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of HPLC and LC-MS/MS methods for the analysis of ivacaftor, its major metabolites and lumacaftor in plasma and sputum of cystic fibrosis patients treated with ORKAMBI or KALYDECO.
    Schneider EK; Reyes-Ortega F; Wilson JW; Kotsimbos T; Keating D; Li J; Velkov T
    J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Dec; 1038():57-62. PubMed ID: 27792891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lumacaftor/ivacaftor combination for cystic fibrosis patients homozygous for Phe508del-CFTR.
    Zhang W; Zhang X; Zhang YH; Strokes DC; Naren AP
    Drugs Today (Barc); 2016 Apr; 52(4):229-37. PubMed ID: 27252987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tezacaftor/Ivacaftor (Symdeko) for cystic fibrosis.
    Med Lett Drugs Ther; 2018 Oct; 60(1558):174-176. PubMed ID: 30335045
    [No Abstract]   [Full Text] [Related]  

  • 7. Ivacaftor for patients with cystic fibrosis.
    Wainwright CE
    Expert Rev Respir Med; 2014 Oct; 8(5):533-8. PubMed ID: 25148205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lumacaftor/ivacaftor (Orkambi) for cystic fibrosis.
    Med Lett Drugs Ther; 2016 Mar; 58(1491):41-2. PubMed ID: 27027688
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacokinetic interactions between ivacaftor and cytochrome P450 3A4 inhibitors in people with cystic fibrosis and healthy controls.
    van der Meer R; Wilms EB; Sturm R; Heijerman HGM
    J Cyst Fibros; 2021 Sep; 20(5):e72-e76. PubMed ID: 34006500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The safety of lumacaftor and ivacaftor for the treatment of cystic fibrosis.
    Talamo Guevara M; McColley SA
    Expert Opin Drug Saf; 2017 Nov; 16(11):1305-1311. PubMed ID: 28846049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.
    Kuk K; Taylor-Cousar JL
    Ther Adv Respir Dis; 2015 Dec; 9(6):313-26. PubMed ID: 26416827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lumacaftor/Ivacaftor: A Review in Cystic Fibrosis.
    Deeks ED
    Drugs; 2016 Aug; 76(12):1191-201. PubMed ID: 27394157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo and in vitro ivacaftor response in cystic fibrosis patients with residual CFTR function: N-of-1 studies.
    McGarry ME; Illek B; Ly NP; Zlock L; Olshansky S; Moreno C; Finkbeiner WE; Nielson DW
    Pediatr Pulmonol; 2017 Apr; 52(4):472-479. PubMed ID: 28068001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled trial.
    Davies J; Sheridan H; Bell N; Cunningham S; Davis SD; Elborn JS; Milla CE; Starner TD; Weiner DJ; Lee PS; Ratjen F
    Lancet Respir Med; 2013 Oct; 1(8):630-638. PubMed ID: 24461666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (VX-770, ivacaftor), a potent and orally bioavailable CFTR potentiator.
    Hadida S; Van Goor F; Zhou J; Arumugam V; McCartney J; Hazlewood A; Decker C; Negulescu P; Grootenhuis PD
    J Med Chem; 2014 Dec; 57(23):9776-95. PubMed ID: 25441013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nutritional Status Improved in Cystic Fibrosis Patients with the G551D Mutation After Treatment with Ivacaftor.
    Borowitz D; Lubarsky B; Wilschanski M; Munck A; Gelfond D; Bodewes F; Schwarzenberg SJ
    Dig Dis Sci; 2016 Jan; 61(1):198-207. PubMed ID: 26250833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ivacaftor and sinonasal pathology in a cystic fibrosis patient with genotype deltaF508/S1215N.
    Vreede CL; Berkhout MC; Sprij AJ; Fokkens WJ; Heijerman HG
    J Cyst Fibros; 2015 May; 14(3):412-3. PubMed ID: 25169789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cystic Fibrosis Transmembrane Conductance Regulator Potentiation as a Therapeutic Strategy for Pulmonary Edema: A Proof-of-Concept Study in Pigs.
    Li X; Vargas Buonfiglio LG; Adam RJ; Stoltz DA; Zabner J; Comellas AP
    Crit Care Med; 2017 Dec; 45(12):e1240-e1246. PubMed ID: 28953499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Forecasting the Long-Term Clinical and Economic Outcomes of Lumacaftor/Ivacaftor in Cystic Fibrosis Patients with Homozygous phe508del Mutation.
    Dilokthornsakul P; Patidar M; Campbell JD
    Value Health; 2017 Dec; 20(10):1329-1335. PubMed ID: 29241892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Computed tomography correlates with improvement with ivacaftor in cystic fibrosis patients with G551D mutation.
    Sheikh SI; Long FR; McCoy KS; Johnson T; Ryan-Wenger NA; Hayes D
    J Cyst Fibros; 2015 Jan; 14(1):84-9. PubMed ID: 25049054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.